Alliance Global Partners analyst Scott Henry raised the firm’s price target on Journey Medical (DERM) to $11 from $8.50 and reiterated a Buy rating on the shares. The firm noted the “underwhelmed” reaction to Journey’s announcement the FDA approved Emrosi as a 1x/day oral treatment for rosacea, but feels that longer term this is a “transformative event for the company” and reiterated its Buy rating for speculative investors.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.